Cargando…
Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan
The oral poliovirus vaccine (OPV) has been the mainstay of polio eradication, especially in low-income countries, and its use has eliminated wild poliovirus type 2. However, the inactivated poliovirus vaccine (IPV) is safer than OPV, as IPV protects against paralytic poliomyelitis without producing...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534550/ https://www.ncbi.nlm.nih.gov/pubmed/37766121 http://dx.doi.org/10.3390/vaccines11091444 |
_version_ | 1785112420938678272 |
---|---|
author | Habib, Muhammad Atif Soofi, Sajid Bashir Hussain, Imtiaz Ahmed, Imran Hussain, Zamir Tahir, Rehman Anwar, Saeed Cousens, Simon Bhutta, Zulfiqar A. |
author_facet | Habib, Muhammad Atif Soofi, Sajid Bashir Hussain, Imtiaz Ahmed, Imran Hussain, Zamir Tahir, Rehman Anwar, Saeed Cousens, Simon Bhutta, Zulfiqar A. |
author_sort | Habib, Muhammad Atif |
collection | PubMed |
description | The oral poliovirus vaccine (OPV) has been the mainstay of polio eradication, especially in low-income countries, and its use has eliminated wild poliovirus type 2. However, the inactivated poliovirus vaccine (IPV) is safer than OPV, as IPV protects against paralytic poliomyelitis without producing adverse reactions. The present study compared mucosal and humoral responses to poliovirus vaccines administered to previously OPV-immunized children to assess the immunity gap in children in areas of high poliovirus transmission. A cluster-randomized trial was implemented in three high-risk districts of Pakistan—Karachi, Kashmore, and Bajaur—from June 2013 to May 2014. This trial was community-oriented and included three arms, focusing on healthy children below five years of age. The study involved the randomization of 387 clusters, of which 360 were included in the final analysis. The control arm (A) received the routine polio program bivalent poliovirus vaccine (bOPV). The second arm (B) received additional interventions, including health camps providing routine vaccinations and preventive maternal and child health services. In addition to the interventions in arm B, the third arm (C) was also provided with IPV. Blood and stool samples were gathered from children to evaluate humoral and intestinal immunity. The highest levels of poliovirus type 1 serum antibodies were observed in Group C (IPV + OPV). The titers for poliovirus type 2 (P2) and poliovirus type 3 (P3) were noticeably higher in those who had received a routine OPV dose than in those who had not across all study groups and visits. Providing an IPV booster after at least two OPV doses could potentially fill immunity gaps in regions where OPV does not show high efficacy. However, IPV only marginally enhances humoral immunity and fails to offer intestinal immunity, which is critical to stop the infection and spread of live poliovirus in populations that have not been exposed before. |
format | Online Article Text |
id | pubmed-10534550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105345502023-09-29 Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan Habib, Muhammad Atif Soofi, Sajid Bashir Hussain, Imtiaz Ahmed, Imran Hussain, Zamir Tahir, Rehman Anwar, Saeed Cousens, Simon Bhutta, Zulfiqar A. Vaccines (Basel) Article The oral poliovirus vaccine (OPV) has been the mainstay of polio eradication, especially in low-income countries, and its use has eliminated wild poliovirus type 2. However, the inactivated poliovirus vaccine (IPV) is safer than OPV, as IPV protects against paralytic poliomyelitis without producing adverse reactions. The present study compared mucosal and humoral responses to poliovirus vaccines administered to previously OPV-immunized children to assess the immunity gap in children in areas of high poliovirus transmission. A cluster-randomized trial was implemented in three high-risk districts of Pakistan—Karachi, Kashmore, and Bajaur—from June 2013 to May 2014. This trial was community-oriented and included three arms, focusing on healthy children below five years of age. The study involved the randomization of 387 clusters, of which 360 were included in the final analysis. The control arm (A) received the routine polio program bivalent poliovirus vaccine (bOPV). The second arm (B) received additional interventions, including health camps providing routine vaccinations and preventive maternal and child health services. In addition to the interventions in arm B, the third arm (C) was also provided with IPV. Blood and stool samples were gathered from children to evaluate humoral and intestinal immunity. The highest levels of poliovirus type 1 serum antibodies were observed in Group C (IPV + OPV). The titers for poliovirus type 2 (P2) and poliovirus type 3 (P3) were noticeably higher in those who had received a routine OPV dose than in those who had not across all study groups and visits. Providing an IPV booster after at least two OPV doses could potentially fill immunity gaps in regions where OPV does not show high efficacy. However, IPV only marginally enhances humoral immunity and fails to offer intestinal immunity, which is critical to stop the infection and spread of live poliovirus in populations that have not been exposed before. MDPI 2023-09-01 /pmc/articles/PMC10534550/ /pubmed/37766121 http://dx.doi.org/10.3390/vaccines11091444 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Habib, Muhammad Atif Soofi, Sajid Bashir Hussain, Imtiaz Ahmed, Imran Hussain, Zamir Tahir, Rehman Anwar, Saeed Cousens, Simon Bhutta, Zulfiqar A. Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan |
title | Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan |
title_full | Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan |
title_fullStr | Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan |
title_full_unstemmed | Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan |
title_short | Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan |
title_sort | does ipv boost intestinal immunity among children under five years of age? an experience from pakistan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534550/ https://www.ncbi.nlm.nih.gov/pubmed/37766121 http://dx.doi.org/10.3390/vaccines11091444 |
work_keys_str_mv | AT habibmuhammadatif doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT soofisajidbashir doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT hussainimtiaz doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT ahmedimran doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT hussainzamir doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT tahirrehman doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT anwarsaeed doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT cousenssimon doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan AT bhuttazulfiqara doesipvboostintestinalimmunityamongchildrenunderfiveyearsofageanexperiencefrompakistan |